Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 12:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 1,695 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Vehicle Clear all
Withdrawn Phase 1Phase 2 Interventional

Pharmacology of Exenatide in Pediatric Sepsis

NCT01573806
View directory record Official record
Conditions
Septic Shock, Inflammation, Glucose Homeostasis, Organ Dysfunction, Health-related Quality of Life
Interventions
Exenatide, Exenatide vehicle
Drug
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
1 Month to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 5, 2017 · Synced Oct 18, 2026, 12:27 AM EDT
Completed Phase 2 Interventional

Efficacy, Safety, and Tolerability of S6G5T-1 and S6G5T-3 for the Treatment of Acne Vulgaris

NCT02661958
View directory record Official record
Conditions
Acne Vulgaris
Interventions
S6G5T-3, S6G5T-1, S6G5T-5, S6G5T-6, S6G5T-7, S6G5T-8
Drug
Lead sponsor
Sol-Gel Technologies, Ltd.
Industry
Eligibility
9 Years and older
Enrollment
726 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
34
States / cities
Anaheim, California • Cerritos, California • Chula Vista, California + 27 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2019 · Synced Oct 18, 2026, 12:27 AM EDT
Completed Not applicable Interventional Results available

Utilizing Text Messaging to Improve Vehicle Safety Among At-Risk Young Adults

NCT03833713
View directory record Official record
Conditions
Risk Reduction
Interventions
SMS Dialogue, SMS Assessments
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 25 Years
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 9, 2024 · Synced Oct 18, 2026, 12:27 AM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Trial of Treatment of Atopic Dermatitis With Concurrent Altabax® and Topical Low-Potency Corticosteroids Versus Low-Potency Corticosteroid Mono-therapy

NCT00871208
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Altabax (R), Vehicle and Locoid lipocream (R)
Drug
Lead sponsor
St. Luke's-Roosevelt Hospital Center
Other
Eligibility
9 Months to 17 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
3
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 12, 2015 · Synced Oct 18, 2026, 12:27 AM EDT
Completed No phase listed Observational

Persistent Pain Among Elderly Experiencing Motor Vehicle Collision

NCT02054962
View directory record Official record
Conditions
Persistent Pain After Injury, Functional Decline After Injury
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
65 Years and older
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Grand Rapids, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 5, 2018 · Synced Oct 18, 2026, 12:27 AM EDT
Completed No phase listed Observational

A Prospective, Noninterventional Follow-Up Study of Children Aged 23 to 25 Months, Born to Mothers Who Received Hydroxyprogesterone Caproate Injection, 250 mg/mL, or Vehicle for Prevention of Preterm Birth

NCT01146990
View directory record Official record
Conditions
Children Whose Mothers Received 17P and Those Who Received Vehicle in the 17P Efficacy Trial
Interventions
ASQ-3, Bayley III, Neurologic exam
Drug
Lead sponsor
AMAG Pharmaceuticals, Inc.
Industry
Eligibility
22 Months to 25 Months
Enrollment
245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
24
States / cities
Montgomery, Alabama • Tucson, Arizona • La Mesa, California + 19 more
Source: ClinicalTrials.gov public record
Updated May 18, 2022 · Synced Oct 18, 2026, 12:27 AM EDT
Enrolling by invitation Phase 1Phase 2 Interventional

Topical Insulin for Glaucoma (TING2)

NCT07619482
View directory record Official record
Conditions
Open Angle Glaucoma, Primary Open Angle Glaucoma, Low Tension Glaucoma, Pigmentary Glaucoma, Pseudoexfoliation Glaucoma
Interventions
EYED-002 Low Dose (721 U/mL topical insulin), EYED-002 High Dose (1442 U/mL topical insulin), EYED-002 (highest tolerated dose, 12-month), Vehicle Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 90 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 18, 2026, 12:27 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Preventing Distracted Driving Phase II

NCT05608018
View directory record Official record
Conditions
Distracted Driving
Interventions
Intervention Bluetooth, Intervention non-Bluetooth, Control Bluetooth, Control non-Bluetooth
Other
Lead sponsor
Minnesota HealthSolutions
Industry
Eligibility
16 Years to 75 Years
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 6, 2025 · Synced Oct 18, 2026, 12:27 AM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

Teen Driving Translation Study (NIH)

NCT05696353
View directory record Official record
Conditions
Drive, Recidivism, Communication, Feedback, Psychological
Interventions
In-vehicle Device, Expert-Delivered Parent Communication Training, Peer-Delivered Parent Communication Training
Combination Product · Behavioral
Lead sponsor
Ginger Yang
Other
Eligibility
16 Years to 18 Years
Enrollment
588 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 18, 2026, 12:27 AM EDT
Completed Phase 2 Interventional Results available

Dose Range Study of CD5789 in Acne Vulgaris

NCT01616654
View directory record Official record
Conditions
Acne Vulgaris
Interventions
CD5789 25 µg/g cream, CD5789 50 µg/g cream, CD5789 100 µg/g cream, Tazarotene 0.1% gel, Vehicle cream
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
12 Years to 35 Years
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
24
States / cities
Birmingham, Alabama • Glendale, California • Marina del Rey, California + 21 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2021 · Synced Oct 18, 2026, 12:27 AM EDT
Recruiting Phase 2 Interventional

A Multicenter, Randomized, Vehicle-Controlled, Double-Masked to Open-Label Study to Evaluate the Safety and Efficacy of Lacripep in Subjects With Neurotrophic Keratitis

NCT07568730
View directory record Official record
Conditions
Neurotrophic Keratitis
Interventions
Lacripep, Vehicle Ophthalmic Solution
Drug · Other
Lead sponsor
TearSolutions, Inc.
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
6
States / cities
Tampa, Florida • Carmel, Indiana • Russells Mills, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 18, 2026, 12:27 AM EDT
Completed Phase 3 Interventional Results available

Metvix PDT Versus Vehicle PDT With Aktilite CL128 Lamp in Patients With Actinic Keratosis on the Face and Scalp

NCT00304239
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Metvix-PDT, Vehicle-PDT
Combination Product
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
4
States / cities
Naperville, Illinois • Louisville, Kentucky • Portland, Oregon + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2023 · Synced Oct 18, 2026, 12:27 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Safety and Tolerability of Hair Stimulating Complex (HSC) in Female Pattern Hair Loss

NCT03662854
View directory record Official record
Conditions
Alopecia
Interventions
Hair Stimulating Complex (HSC), Phosphate Buffered Saline
Biological · Other
Lead sponsor
Histogen
Industry
Eligibility
40 Years to 70 Years · Female only
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Feb 21, 2019 · Synced Oct 18, 2026, 12:27 AM EDT
Completed Phase 3 Interventional

Study of Difluprednate in the Treatment of Inflammation Following Ocular Surgery (ST-601-003)

NCT00616070
View directory record Official record
Conditions
Inflammation
Interventions
Difluprednate, Placebo
Drug · Other
Lead sponsor
Sirion Therapeutics, Inc.
Industry
Eligibility
2 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 30, 2011 · Synced Oct 18, 2026, 12:27 AM EDT
Completed Phase 3 Interventional Results available

Adapalene-BPO Gel Associated With Doxycycline Hyclate 100 mg in the Treatment of Severe Acne Vulgaris

NCT00688064
View directory record Official record
Conditions
Severe Acne Vulgaris
Interventions
Adapalene BPO Gel associated with Doxycyline Hyclate, Vehicle Gel associated with Doxycycline Hyclate
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
12 Years to 35 Years
Enrollment
459 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
28
States / cities
Oceanside, California • San Diego, California • Denver, Colorado + 25 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2021 · Synced Oct 18, 2026, 12:27 AM EDT
Completed Not applicable Interventional

Reducing Isolation and Feeling of Loneliness During Critical Illness

NCT05537311
View directory record Official record
Conditions
Critical Illness, Social Isolation, Anxiety, Depression, Post Intensive Care Unit Syndrome
Interventions
Social Engagement
Behavioral
Lead sponsor
Kirby Mayer
Other
Eligibility
18 Years to 99 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jul 14, 2023 · Synced Oct 18, 2026, 12:27 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Safety Assessment of T4090 Eye Drops in Ocular Hypertensive or Glaucomatous Patients.

NCT05389267
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
Kinezodianone R hydrochloride, Placebo
Drug
Lead sponsor
Laboratoires Thea
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Feb 7, 2024 · Synced Oct 18, 2026, 12:27 AM EDT
Active, not recruiting Early Phase 1 Interventional Accepts healthy volunteers

Role of NADPH Oxidase in Microvascular Dysfunction Following GDM

NCT05946798
View directory record Official record
Conditions
Gestational Diabetes, Oxidative Stress, Vascular Endothelial Function
Interventions
Acetylcholine, Insulin aspart
Drug
Lead sponsor
Anna Stanhewicz, PhD
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 18, 2026, 12:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Tolerability of PNT001 in Healthy Adults

NCT04096287
View directory record Official record
Conditions
Healthy
Interventions
PNT001, Placebo
Biological · Drug
Lead sponsor
Pinteon Therapeutics, Inc
Industry
Eligibility
21 Years to 65 Years
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
4
States / cities
Rogers, Arkansas • San Diego, California • Marlton, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2021 · Synced Oct 18, 2026, 12:27 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Moderate to Severe Acne Vulgaris With Photodynamic Therapy in Adults

NCT05080764
View directory record Official record
Conditions
Acne Vulgaris
Interventions
1h Incubation Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT), 1h Incubation Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient), 3h Incubation Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT), 3h Incubation Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient)
Combination Product
Lead sponsor
Biofrontera Inc.
Industry
Eligibility
16 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
9
States / cities
Fountain Valley, California • San Diego, California • Delray Beach, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 18, 2026, 12:27 AM EDT
Not yet recruiting Phase 2 Interventional

Controlled Study, Performed to Evaluate the Safety and Efficacy of EscharEx and Its Placebo (Gel Vehicle) Compared to Non-surgical Standard of Care in Participants With Venous Leg Ulcers (VLU)

NCT06690177
View directory record Official record
Conditions
Venus Leg Ulcers
Interventions
EscharEx (EX-03), Placebo (Gel vehicle), Non-surgical standard of care (NSSOC)
Drug · Other
Lead sponsor
MediWound Ltd
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2029
U.S. locations
1
States / cities
Maimi, Florida
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 18, 2026, 12:27 AM EDT
Terminated Not applicable Interventional Results available

Efficacy of Nalbuphine and Naloxone Administered as Nose Sprays in the Treatment of Orofacial Pain

NCT00716807
View directory record Official record
Conditions
Temporomandibular Joint Dysfunction Syndrome, Burning Mouth Syndrome
Interventions
nalbuphine plus naloxone, nalbuphine plus placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 20, 2016 · Synced Oct 18, 2026, 12:27 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Spinal and Supra-Spinal Pain Mechanisms in Patients With Fibromyalgia

NCT03464292
View directory record Official record
Conditions
Fibromyalgia, Pain
Interventions
Capsaicin Patch 8% or 0.1% Capsaicin Cream, Vehicle Patch
Drug · Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 65 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Dec 14, 2023 · Synced Oct 18, 2026, 12:27 AM EDT
Recruiting Phase 1Phase 2 Interventional

Therapeutic Contact Lens Drug Delivery System (TCL-DDS) in Patients With Recurrent Cystoid Macular Edema

NCT04225611
View directory record Official record
Conditions
Cystoid Macular Edema
Interventions
Dexamethasone
Drug
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years to 85 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 26, 2025 · Synced Oct 18, 2026, 12:27 AM EDT